Table 2.

Recommendations for treatment of community‐acquired respiratory virus infection

Antiviral therapy with oseltamivir or zanamivir should be administered to solid organ transplant (SOT) recipients with a clinical suspicion of influenza infection, before laboratory confirmation, irrespective of the duration of symptoms. AII

Treatment of influenza with M2 inhibitors (amantadine and rimantadine) is not recommended. DII

In the absence of a concern over drug absorption, a double dose of oseltamivir (i.e. 150 mg BID) is not recommended. CI

The use of intravenous zanamivir or peramivir can be considered in patients not responding to oseltamivir therapy or for whom oral absorption is a concern. BII

In severe cases of low respiratory tract infection with respiratory syncytial virus (RSV) and parainfluenza virus (PIV) infections in SOT recipients, therapy with aerosolized or oral ribavirin may be used. BII

Intravenous immunoglobulin can be combined with antiviral therapy in severe cases of RSV and PIV infection. BIII

There are insufficient data to recommend therapy with ribavirin in lung transplant recipients with non‐severe cases of RSV or PIV infection. CIII

The use of ribavirin may be considered in severe cases of hMPV infection. CIII

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.